Published: Sat, May 20, 2017
Business | By Max Garcia

Where is ACADIA Pharmaceuticals Inc. (ACAD) Heading Next?


It turned negative, as 42 investors sold ACADIA Pharmaceuticals Inc. shares while 58 reduced holdings. (NASDAQ:ACAD), with 6 analysts believing it is a strong buy.

01/18/2017 - ACADIA Pharmaceuticals Inc. had its "outperform" rating reiterated by analysts at Cowen. The company is expected to announce its next earnings results after the market closes on Tuesday, May 9th. On average, analysts anticipate that ACADIA Pharmaceuticals will post ($2.83) EPS for the current year. This estimate is provided by 20120 analysts. Zacks' sales calculations are an average based on a survey of sell-side research firms that follow ACADIA Pharmaceuticals. The stock appeared -12.30% below its 52-week highs and is up 6.30% for the last five trades. The company beat the analyst EPS Estimate with the difference of $0.01. Revenue during the period amounted to $11.96M, while analysts were anticipating $9.05M.

Several analysts have released their opinion on ACADIA Pharmaceuticals Inc. During the same quarter in the previous year, the company posted ($0.45) earnings per share.

The Stock had a 1.67 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.75 and 1.75 respectively. Vetr downgraded shares of ACADIA Pharmaceuticals from a "strong-buy" rating to a "buy" rating and set a $37.64 price target on the stock.in a research note on Tuesday, January 31st. JPMorgan Chase & Co. restated a buy rating on shares of ACADIA Pharmaceuticals in a report on Wednesday, January 11th. Finally, Piper Jaffray Companies reaffirmed an "overweight" rating and issued a $44.00 price target on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 7th. They set a buy rating and a $48.00 target price on the stock.

The company's consensus rating is now Strong Buy, with 6 analysts rating it a Strong Buy, and 3 analysts rating it with a Hold. In a transaction dated February 14, 2017, the shares were put up for sale at an average price of $39.66, raking in a sum of $1,045,636. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Similar statistics are true for the second largest owner, Fmr Llc, which owns 18,211,143 shares of the stock are valued at $517.2 million. Baker BROS. Advisors LP bought a new position in shares of ACADIA Pharmaceuticals during the third quarter worth about $821,327,000. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) now has a Piotroski Score of 3. California State Teachers Retirement System now owns 204,060 shares of the biopharmaceutical company's stock worth $6,491,000 after buying an additional 12,800 shares in the last quarter. Elliott Management Corp acquired a new stake in ACADIA Pharmaceuticals during the first quarter valued at approximately $26,726,000. BlackRock Inc. now owns 5,433,209 shares of the biopharmaceutical company's stock worth $186,791,000 after buying an additional 5,334,832 shares during the last quarter. Hedge funds and other institutional investors own 98.25% of the company's stock.

Shares of ACADIA Pharmaceuticals Inc. If you are reading this piece on another domain, it was copied illegally and reposted in violation of US and worldwide trademark & copyright law. (NASDAQ:ACAD) traded up 0.92% during trading on Thursday, reaching $27.31. The third largest holder is Vanguard Group Inc, which now holds $212.14 million worth of this stock and that ownership represents almost 6.47% of its market capitalization.

ACADIA Pharmaceuticals Inc. has a 50 day moving average of 32.18 and a 200 day moving average of 31.92. The company's 52-week range is $20.68 to $42.49.

ACADIA Pharmaceuticals Inc. (ACAD) has the market capitalization of $3.31 Billion. The Firm is focused on the development and commercialization of medicines for central nervous system disorders. The Company's lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis).

Like this: